Company News-Novamab

2024-09-30

Good news! Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2024

From September 8th to September 10th, the Huayi List · 2024 China Biomedical Technology Innovation Value List, jointly initiated by Yiyun Technology and the National Technology Transfer Eastern Center

More

2024-07-31

Novamab, the world's first inhaled nanobodycompany, officially announced the completion of nearly 300 million RMB in Series B financing

Shanghai, China, July 31, 2024- Shanghai Novamab Biopharmaceuticals Co., Ltd. (the "Company" or "Novamab"), a biotechnology company dedicated to the research and development of innovative nanobody drugs, officially announced the completion of its Series B2 financing of nearly 200 millionRMB, which was led by Qiming Venture Capital, with participation of Huangpu Biopharmaceutical Fund and Jiuyu Investment.

More

2024-05-11

International Conference 及2024 BIO International Convention

Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun

More

2024-04-23

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients

Shanghai, China, April 23, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced that its core product LQ036 (an IL-4Rα single-domain

More

2024-03-05

BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab

Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of

More

2024-02-29

Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level

Shanghai, February 29, 2024 - Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced the research progress on the development and scaling up

More

2024-02-22

Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP Nanobody Drug LQ043H in Healthy Chinese Subjects

Shanghai, February 22, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nonobody drugs, announced today the results of the tolerance, safety, pharmacokine

More

2023-12-19

Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan

On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.

More

2023-11-13

The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!

Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p

More

2023-09-26

Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference

More